IL298168A - Multispecific proteins - Google Patents
Multispecific proteinsInfo
- Publication number
- IL298168A IL298168A IL298168A IL29816822A IL298168A IL 298168 A IL298168 A IL 298168A IL 298168 A IL298168 A IL 298168A IL 29816822 A IL29816822 A IL 29816822A IL 298168 A IL298168 A IL 298168A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- recombinant protein
- fap
- amino acid
- binding domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174847 | 2020-05-14 | ||
| EP20181498 | 2020-06-22 | ||
| PCT/EP2021/062860 WO2021229067A1 (en) | 2020-05-14 | 2021-05-14 | Multispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298168A true IL298168A (en) | 2023-01-01 |
Family
ID=75904957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298168A IL298168A (en) | 2020-05-14 | 2021-05-14 | Multispecific proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240279290A1 (https=) |
| EP (1) | EP4149959A1 (https=) |
| JP (1) | JP7843711B2 (https=) |
| KR (1) | KR20230022176A (https=) |
| CN (1) | CN115768786A (https=) |
| AU (1) | AU2021271129A1 (https=) |
| BR (1) | BR112022023049A2 (https=) |
| CA (1) | CA3178785A1 (https=) |
| CO (1) | CO2022017445A2 (https=) |
| IL (1) | IL298168A (https=) |
| MX (1) | MX2022014326A (https=) |
| TW (1) | TW202208408A (https=) |
| WO (1) | WO2021229067A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220113492A (ko) | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| IL305677A (en) | 2021-03-09 | 2023-11-01 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| IL313411A (en) * | 2021-12-14 | 2024-08-01 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| BRPI0613593A2 (pt) | 2005-07-08 | 2011-01-18 | Univ Zuerich | método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| DK2643349T3 (da) | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| CA2877584A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| CA2883264A1 (en) | 2012-10-15 | 2014-04-24 | Universitat Zurich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| AU2016240220B2 (en) | 2015-04-02 | 2019-11-21 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| US10717772B2 (en) | 2016-09-22 | 2020-07-21 | Molecular Partners Ag | Recombinant binding proteins targeting HER2 and serum albumin, and their uses |
| AU2018247796A1 (en) * | 2017-04-04 | 2019-08-29 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP |
| KR102782136B1 (ko) | 2017-11-08 | 2025-03-18 | 쿄와 기린 가부시키가이샤 | CD40과 EpCAM에 결합하는 이중특이적 항체 |
| NZ773887A (en) | 2018-10-01 | 2024-11-29 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| US12441772B2 (en) | 2019-06-04 | 2025-10-14 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| SG11202112925PA (en) | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| CN114206943A (zh) | 2019-06-04 | 2022-03-18 | 分子伴侣公司 | 多特异性蛋白质 |
| KR20220113492A (ko) | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| CA3161319A1 (en) | 2019-12-11 | 2021-06-17 | Victor LEVITSKY | Recombinant peptide-mhc complex binding proteins and their generation and use |
| KR20230006558A (ko) | 2020-05-06 | 2023-01-10 | 몰리큘라 파트너스 아게 | 신규한 안키린 반복 결합 단백질 및 그의 용도 |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US20240279309A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| JP2023549316A (ja) | 2020-11-16 | 2023-11-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法 |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| US20240052033A1 (en) | 2020-12-16 | 2024-02-15 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| TW202300644A (zh) | 2021-02-24 | 2023-01-01 | 中國大陸商杭州啟函生物科技有限公司 | 免疫細胞中的嵌合抗原受體 |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| WO2022190010A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| EP4319883A1 (en) | 2021-04-09 | 2024-02-14 | Molecular Partners AG | Novel darpin based cd70 engagers |
| IL313411A (en) | 2021-12-14 | 2024-08-01 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
-
2021
- 2021-05-14 IL IL298168A patent/IL298168A/en unknown
- 2021-05-14 TW TW110117538A patent/TW202208408A/zh unknown
- 2021-05-14 WO PCT/EP2021/062860 patent/WO2021229067A1/en not_active Ceased
- 2021-05-14 MX MX2022014326A patent/MX2022014326A/es unknown
- 2021-05-14 AU AU2021271129A patent/AU2021271129A1/en active Pending
- 2021-05-14 US US17/925,144 patent/US20240279290A1/en active Pending
- 2021-05-14 BR BR112022023049A patent/BR112022023049A2/pt unknown
- 2021-05-14 KR KR1020227043615A patent/KR20230022176A/ko active Pending
- 2021-05-14 CN CN202180044299.9A patent/CN115768786A/zh active Pending
- 2021-05-14 JP JP2022568689A patent/JP7843711B2/ja active Active
- 2021-05-14 CA CA3178785A patent/CA3178785A1/en active Pending
- 2021-05-14 EP EP21725187.5A patent/EP4149959A1/en active Pending
- 2021-05-14 US US17/302,898 patent/US12331090B2/en active Active
-
2022
- 2022-12-02 CO CONC2022/0017445A patent/CO2022017445A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023528204A (ja) | 2023-07-04 |
| TW202208408A (zh) | 2022-03-01 |
| JP7843711B2 (ja) | 2026-04-10 |
| BR112022023049A2 (pt) | 2022-12-20 |
| MX2022014326A (es) | 2023-02-09 |
| AU2021271129A1 (en) | 2022-12-15 |
| CO2022017445A2 (es) | 2023-02-16 |
| KR20230022176A (ko) | 2023-02-14 |
| CN115768786A (zh) | 2023-03-07 |
| WO2021229067A1 (en) | 2021-11-18 |
| US20210395318A1 (en) | 2021-12-23 |
| AU2021271129A9 (en) | 2023-01-12 |
| US20240279290A1 (en) | 2024-08-22 |
| CA3178785A1 (en) | 2021-11-18 |
| EP4149959A1 (en) | 2023-03-22 |
| US12331090B2 (en) | 2025-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298168A (en) | Multispecific proteins | |
| US20240025961A1 (en) | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 | |
| TWI839365B (zh) | 間皮素及cd137結合分子 | |
| IL272137B1 (en) | Interleukin-21 muteins and methods of treatment | |
| CN111727197A (zh) | 抗pd-1抗体和治疗方法 | |
| CN115087670B (zh) | 包含ltbr和edb结合结构域的多特异性结合分子及其用途 | |
| JP2020503245A (ja) | 抗ヒト４−１ｂｂ抗体およびその使用 | |
| WO2020061376A2 (en) | Methods and uses of variant cd80 fusion proteins and related constructs | |
| JP2025534285A (ja) | プロテアーゼ活性化ポリペプチド | |
| WO2023235703A1 (en) | Therapeutic methods using ilt-binding agents | |
| WO2021000953A1 (zh) | 治疗肿瘤的物质和方法 | |
| WO2025189977A1 (zh) | 一种抗vegfa融合构建体及其制备方法和应用 | |
| WO2024251742A1 (en) | Recombinant cd2 binding proteins and their use | |
| HK40060137A (en) | Methods and uses of variant cd80 fusion proteins and related constructs | |
| HK1245288B (en) | Car t-cells recognizing cancer-specific il 13r-alpha2 | |
| HK1189901A (en) | Mutant interleukin-2 polypeptides | |
| HK1217020A1 (zh) | 突变体白介素-2多肽 | |
| HK1189901B (en) | Mutant interleukin-2 polypeptides |